Fig. 2

Methyltransferase-like 3 was substantially increased in colorectal carcinoma and associated with poor prognosis. Methyltransferase-like 3 (METTL3) expression in both adenoma and colorectal carcinoma (CRC) was assayed through (a) Western blot, b Immunohistochemistry (IHC), and c Immunofluorescence. d N6-methyladnosine (m6A) methylase activity was assayed. e METTL3 mRNA level in CRC cells; f METTL3 protein level in CRC cells; g Representative images of IHC staining for METTL3 level as obtained from 100 CRC tissues and 80 normal tissues; h METTL3 IHC staining scores; i Kaplan–Meier overall survival analysis of METTL3 expression in patients with CRC. Data are presented as means ± standard deviations (SDs). ^*P < 0.05, ^**P < 0.01, ^***P < 0.001